News
Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use ...
In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...
The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...
Drugmaker Eli Lilly ... high cholesterol. Lilly has a strong portfolio of GLP-1 drugs that have helped propel its growth. Last quarter alone, its two leading GLP-1 drugs, Mounjaro and Zepbound ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...
Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes ...
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. In March this year, U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results